Bristol-Myers Squibb’s YERVOY® Wins Prix Galien USA Prize

By jolene / 19 October 2012 / 0 comments

On Wednesday, Bristol-Myers Squibb Company announced that YERVOY® (ipilimumab) had received the Prix Galien USA 2012 Award for Best Biotechnology Product. YERVOY® falls in the field of immuno-oncology, which is the science of harnessing the immune system to fight cancer. By prioritizing immuno-oncology in the area of R&D at Bristol-Myers Squibb, the global biopharmaceutical company is exploring a variety of approaches to help address unmet medical needs in a broad range of cancers.

YERVOY® is an innovative immunotherapy drug and the first one of its kind to be approved in the past ten years. It has also been selected as a finalist for this year’s Prix Galien prize in Germany under the category of specialized care. The Prix Galien Awards were created to honor medical research and pharmacology for outstanding efforts to improve the human condition through approval of innovative treatments and medicines. The awards are selected by a panel that includes several Nobel Laureates. Their objective is to recognize the technical, scientific and clinical research skills and achievements necessary to develop innovative medicines and devices. It is thus considered the most prestigious prize in biopharmaceutical research and development.

Are you interested in interacting with leaders in Asian pharmaceutical R&D? Lucky for you, the BioPharma Asia Convention 2013 will consist of a specialized conference track, Drug Discovery World Asia, which deals specifically with this issues in R&D in biopharma. Some of the themes for this track include:

• Breakthroughs in personalized medicine
• Promising developments in translational medicine
• Innovative technologies in biotherapeutics
• Novel approaches in target identification & validation for infectious diseases
• … And many more.

Those who are interested in the topics mentioned above, please click here to register for the event. If you are interested in exhibiting you research at the convention, click here instead.

Source: Bristol-Myers Squibb